Equity Profile

KRYS

Krystal Biotech, Inc.

Health CareBiotechnology$8.9B

May4Mon

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Krystal Biotech Beats on EPS, Stock Up 7.86%

Metric	Actual	Expected	Surprise
EPS	$1.83	N/A	+26.21%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

Krystal Biotech Beats on EPS, Stock Up 7.86%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.83	N/A	+26.21%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Krystal Biotech reported strong earnings with an EPS of $1.83, exceeding expectations significantly. The stock reacted positively, rising by 7.86%. However, there was no revenue reported or guidance provided, leaving some uncertainty about future performance.

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for patients with rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales, critical for sustaining operations and funding research.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for patients with rare diseases. Operating in the health care sector, it aims to address unmet medical needs through innovative treatments, which is increasingly important as the demand for advanced medical solutions grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In the last quarter, Krystal Biotech reported an EPS of $1.70, exceeding estimates by nearly 5%. The stock reacted positively, gaining over 4% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, there is cautious optimism surrounding Krystal Biotech's upcoming earnings report, especially given its recent performance. Investors are eager to see if the company can maintain its positive momentum.

Bull Case

If Krystal Biotech continues to beat EPS estimates and shows strong revenue growth, it could lead to increased investor confidence and a higher stock price.

Bear Case

Conversely, if the company misses expectations or fails to provide clear guidance on future growth, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

How are R&D expenses trending in relation to revenue growth?

Understanding the balance between R&D spending and revenue growth will provide insights into the company's future prospects and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Krystal Biotech's potential for strong EPS growth due to recent advancements in their pipeline that have not been fully factored into earnings expectations.

Supporting Evidence

Krystal has consistently beaten EPS estimates in recent quarters, suggesting a trend of stronger-than-expected performance.

The options market is pricing in a larger move than historical averages, indicating heightened expectations that could be justified by recent developments.

Key Risk

If the EPS comes in above $1.80, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Krystal Biotech can sustain its recent growth trajectory, making EPS a focal point for this quarter.

Bull Confirmed If

An EPS of $1.80 or higher would confirm the bullish case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would support the bearish case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.51%

Historical Avg

±7.7%

Pricing rich

The options market is pricing in a potential move of about 9.5%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±9.8% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

31.4%

Calls (500)P/C Ratio: 6.96Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal Biotech beats expectations, history suggests a potential stock increase of around 1.55%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess their outlook.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of about 10.23%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of gene therapies and their expected timelines.
2Details on R&D spending and how it aligns with revenue growth.
3Management's outlook on market conditions and competitive landscape.
4Insights into any regulatory updates or approvals that could impact product launches.
5Discussion on partnerships or collaborations that may enhance growth prospects.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

WisdomTree, Inc.

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for patients with rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales, critical for sustaining operations and funding research.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In the last quarter, Krystal Biotech reported an EPS of $1.70, exceeding estimates by nearly 5%. The stock reacted positively, gaining over 4% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Krystal Biotech continues to beat EPS estimates and shows strong revenue growth, it could lead to increased investor confidence and a higher stock price.

Bear Case

Conversely, if the company misses expectations or fails to provide clear guidance on future growth, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

How are R&D expenses trending in relation to revenue growth?

Understanding the balance between R&D spending and revenue growth will provide insights into the company's future prospects and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Krystal Biotech's potential for strong EPS growth due to recent advancements in their pipeline that have not been fully factored into earnings expectations.

Supporting Evidence

Krystal has consistently beaten EPS estimates in recent quarters, suggesting a trend of stronger-than-expected performance.

The options market is pricing in a larger move than historical averages, indicating heightened expectations that could be justified by recent developments.

Key Risk

If the EPS comes in above $1.80, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Krystal Biotech can sustain its recent growth trajectory, making EPS a focal point for this quarter.

Bull Confirmed If

An EPS of $1.80 or higher would confirm the bullish case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would support the bearish case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.51%

Historical Avg

±7.7%

Pricing rich

The options market is pricing in a potential move of about 9.5%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±9.8% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

31.4%

Calls (500)P/C Ratio: 6.96Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal Biotech beats expectations, history suggests a potential stock increase of around 1.55%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess their outlook.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of about 10.23%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of gene therapies and their expected timelines.
2Details on R&D spending and how it aligns with revenue growth.
3Management's outlook on market conditions and competitive landscape.
4Insights into any regulatory updates or approvals that could impact product launches.
5Discussion on partnerships or collaborations that may enhance growth prospects.